(Circulation. 1995;91:1689-1696.)
© 1995 American Heart Association, Inc.
Articles |
Long-term Effects of Angiopeptin Treatment in Coronary Angioplasty
Reduction of Clinical Events but Not Angiographic Restenosis
From Sahlgrenska University Hospital (H.E.), Göteborg, Sweden; Charing X Westminster Hospital (K.J.B.), London; Skejby Hospital (J.-P.B.), Aarhus, Denmark; National Heart and Chest Hospital (R.B.), London; Helsinki (Finland) University Hospital (J.H.); University Ziekenhuizen (J.P.), Leuven, Belgium; The American University (M.S.), Washington, DC; Hospital de Wezenland (H.S.), Zwolle, the Netherlands; and Georgetown University and the Henri Beaufour Institute, USA, Inc. (M.F.), Washington, DC.
Correspondence to Håkan Emanuelsson, MD, Division of Cardiology, Sahlgrenska University Hospital, S-413 45 Göteborg, Sweden.
Background Angiopeptin is a cyclic octapeptide analogue of somatostatin that has been shown to limit myointimal thickening of arteries in balloon injury models and to restore the vasodilating response to acetylcholine. A randomized, double-blind placebo controlled trial was conducted to assess the effect of angiopeptin in restenosis prevention after percutaneous transluminal coronary angioplasty (PTCA).
Methods and Results Patients received a continuous infusion of either placebo or angiopeptin subcutaneously 6 to 24 hours before PTCA and for 4 days after PTCA (3 mg per 24 hours before PTCA followed by 6 mg per 24 hours after PTCA and for the remaining period). A 1.5-mg bolus dose of placebo or angiopeptin was given at PTCA. Aspirin (acetylsalicylic acid, 150 mg/d) was administered throughout the study period. Coronary angiograms obtained before and after PTCA and at 6-month follow-up were subjected to computerized quantification. Clinical follow-up was performed after 12 months. Primary clinical end points were death, myocardial infarction, coronary artery bypass surgery, or repeat PTCA. In total, 553 patients with 742 lesions were randomized. Clinical follow-up was available for all 553 patients. Angiopeptin decreased the clinical events during 12 months of follow-up from 36.4% in the placebo-treated group to 28.4% in the angiopeptin-treated patients (P=.046). Quantitative angiography after PTCA and at follow-up was available in 423 of 455 patients who underwent successful PTCA. The minimal lumen diameter at follow-up was 1.52±0.64 mm in the angiopeptin-treated group compared with 1.52±0.64 mm in the placebo-treated patients (P=.96). The late losses were 0.31±0.59 and 0.30±0.62 mm (P=.81) and the restenosis rates (>50% diameter stenosis at follow-up) were 36% and 37% (P=.85) in the angiopeptin- and placebo-treated groups, respectively.
Conclusions In this study, angiopeptin significantly decreased the incidence of clinical events, principally the rate of revascularization procedures. In contrast, no significant effect was seen on angiographic variables.
Key Words: growth substances • angina • angioplasty • coronary disease
This article has been cited by other articles:
 |
|
 |
|
  M. Y. Wells, H. Voute, M.-O. Lonchampt, C. Fisch, V. Boulifard, and P. Picaut Intimal Hyperplasia in Rats after Subcutaneous Injection of a Somatostatin Analog Toxicol Pathol, February 1, 2009; 37(2): 235 - 243. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Conti, C. Carrozza, E. Capoluongo, M. Volpe, F. Crea, C. Zuppi, and F. Andreotti Insulin-Like Growth Factor-1 as a Vascular Protective Factor Circulation, October 12, 2004; 110(15): 2260 - 2265. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Delafontaine, Y.-H. Song, and Y. Li Expression, Regulation, and Function of IGF-1, IGF-1R, and IGF-1 Binding Proteins in Blood Vessels Arterioscler Thromb Vasc Biol, March 1, 2004; 24(3): 435 - 444. [Abstract] [Full Text]
|
|
|
|
|
|
J. Frystyk, T. Ledet, N. Moller, A. Flyvbjerg, and H. Orskov Cardiovascular Disease and Insulin-Like Growth Factor I Circulation, August 20, 2002; 106(8): 893 - 895. [Full Text] [PDF]
|
|
|
|
 |
|
 M.Y Salame, S Verheye, I.R Crocker, N.A.F Chronos, K.A Robinson, and S.B King III Intracoronary radiation therapy Eur. Heart J., April 2, 2001; 22(8): 629 - 647. [PDF]
|
|
|
|
 |
|
 S. B. Curtis, J. Hewitt, S. Yakubovitz, A. Anzarut, Y. N. Hsiang, and A. M. J. Buchan Somatostatin receptor subtype expression and function in human vascular tissue Am J Physiol Heart Circ Physiol, June 1, 2000; 278(6): H1815 - H1822. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Bayes-Genis, C. A. Conover, and R. S. Schwartz The Insulin-Like Growth Factor Axis : A Review of Atherosclerosis and Restenosis Circ. Res., February 4, 2000; 86(2): 125 - 130. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J Gunn and D Cumberland Stent coatings and local drug delivery. State of the art Eur. Heart J., December 1, 1999; 20(23): 1693 - 1700. [PDF]
|
|
|
|
 |
|
 J Galea, J Armstrong, S.E Francis, G Cooper, D.C Crossman, and C.M Holt Alterations in c-fos expression, cell proliferation and apoptosis in pressure distended human saphenous vein Cardiovasc Res, November 1, 1999; 44(2): 436 - 448. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Bilder, T. Wentz, R. Leadley, D. Amin, L. Byan, B. O'Conner, S. Needle, H. Galczenski, J. Bostwick, C. Kasiewski, et al. Restenosis Following Angioplasty in the Swine Coronary Artery Is Inhibited By an Orally Active PDGF-Receptor Tyrosine Kinase Inhibitor, RPR101511A Circulation, June 29, 1999; 99(25): 3292 - 3299. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. KHARE, U. KUMAR, R. SASI, L. PUEBLA, L. CALDERON, K. LEMSTROM, P. HAYRY, and A. Y. C. PATEL Differential regulation of somatostatin receptor types 1-5 in rat aorta after angioplasty FASEB J, February 1, 1999; 13(2): 387 - 394. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. Gershlick Endovascular manipulation to restrict restenosis Vascular Medicine, August 1, 1998; 3(3): 177 - 188. [Abstract] [PDF]
|
|
|
|
|
|
H. Koyama and M. A. Reidy Expression of Extracellular Matrix Proteins Accompanies Lesion Growth in a Model of Intimal Reinjury Circ. Res., May 19, 1998; 82(9): 988 - 995. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. von Essen, R. Ostermaier, E. Grube, W. Maurer, U. Tebbe, R. Erbel, M. Roth, W. Oel, J. Brom, G. Weidinger, et al. Effects of Octreotide Treatment on Restenosis After Coronary Angioplasty : Results of the VERAS Study Circulation, September 2, 1997; 96(5): 1482 - 1487. [Abstract] [Full Text]
|
|
|
|
|
|
J. Gunn, C. M. Holt, S. E. Francis, L. Shepherd, M. Grohmann, C. M. H. Newman, D. C. Crossman, and D. C. Cumberland The Effect of Oligonucleotides to c-myb on Vascular Smooth Muscle Cell Proliferation and Neointima Formation After Porcine Coronary Angioplasty Circ. Res., April 19, 1997; 80(4): 520 - 531. [Abstract] [Full Text]
|
|
|
|
|
|
E. J. Topol, R. M. Califf, F. Van de Werf, M. Simoons, J. Hampton, K. L. Lee, H. White, J. Simes, and P. W. Armstrong Perspectives on Large-Scale Cardiovascular Clinical Trials for the New Millennium Circulation, February 18, 1997; 95(4): 1072 - 1082. [Full Text]
|
|
|
|
|
|
M. K. Hong, K. M. Kent, R. Mehran, G. S. Mintz, F. O. Tio, M. Foegh, S. C. Wong, S. S. Cathapermal, and M. B. Leon Continuous Subcutaneous Angiopeptin Treatment Significantly Reduces Neointimal Hyperplasia in a Porcine Coronary In-Stent Restenosis Model Circulation, January 21, 1997; 95(2): 449 - 454. [Abstract] [Full Text]
|
|
|
|
|
|
J. Frystyk, C. Skjærbæk, N. Alexander, H. Emanuelsson, H. Suryapranata, H. Beyer, M. Foegh, and H. Orskov Lanreotide Reduces Serum Free and Total Insulin-Like Growth Factor-I After Angioplasty Circulation, November 15, 1996; 94(10): 2465 - 2471. [Abstract] [Full Text]
|
|
|
|
|
|
R. E. Pratt and V. J. Dzau Pharmacological Strategies to Prevent Restenosis : Lessons Learned From Blockade of the Renin-Angiotensin System Circulation, March 1, 1996; 93(5): 848 - 852. [Full Text]
|
|
|
|
|
|
E. J. Topol and S. E. Nissen Our Preoccupation With Coronary Luminology : The Dissociation Between Clinical and Angiographic Findings in Ischemic Heart Disease Circulation, October 15, 1995; 92(8): 2333 - 2342. [Abstract] [Full Text]
|
|